Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (21-30 of 175) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung CancerHollis Viray, Deepa Rangachari, Daniel B Costa
Expert Review of Anticancer Therapy|March 5, 2016
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancerXin Gao, Xiuning Le, Daniel B Costa
Therapeutic Advances in Respiratory Disease|December 2, 2015
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approachesMeghan Shea, Daniel B Costa, Deepa Rangachari
Journal of Thoracic Disease|December 10, 2017
Moving more potent and less toxic options to the frontline in the management of advanced lung cancerXiuning Le, Deepa Rangachari, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant SettingDeepa Rangachari, Paul A VanderLaan, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Erlotinib-associated alopecia in a lung cancer patientDaniel B Costa, Susumu Kobayashi, Susan T Schumer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Management and future directions in non-small cell lung cancer with known activating mutationsDavid E Gerber, Leena Gandhi, Daniel B Costa
Lung Cancer (Amsterdam, Netherlands)|July 13, 2024
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancerMotohiro Izumi, Daniel B Costa, Susumu S Kobayashi
The New England Journal of Medicine|September 14, 2018
Lung Cancer with a High Tumor Mutational BurdenPaul A VanderLaan, Deepa Rangachari, Daniel B Costa
Cancer Cytopathology|August 7, 2020
The rapidly evolving landscape of biomarker testing in non-small cell lung cancerPaul A VanderLaan, Deepa Rangachari, Daniel B Costa
Pageof 18

Showing results (21-30 of 175) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung CancerHollis Viray, Deepa Rangachari, Daniel B Costa
Expert Review of Anticancer Therapy|March 5, 2016
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancerXin Gao, Xiuning Le, Daniel B Costa
Therapeutic Advances in Respiratory Disease|December 2, 2015
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approachesMeghan Shea, Daniel B Costa, Deepa Rangachari
Journal of Thoracic Disease|December 10, 2017
Moving more potent and less toxic options to the frontline in the management of advanced lung cancerXiuning Le, Deepa Rangachari, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant SettingDeepa Rangachari, Paul A VanderLaan, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Erlotinib-associated alopecia in a lung cancer patientDaniel B Costa, Susumu Kobayashi, Susan T Schumer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Management and future directions in non-small cell lung cancer with known activating mutationsDavid E Gerber, Leena Gandhi, Daniel B Costa
Lung Cancer (Amsterdam, Netherlands)|July 13, 2024
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancerMotohiro Izumi, Daniel B Costa, Susumu S Kobayashi
The New England Journal of Medicine|September 14, 2018
Lung Cancer with a High Tumor Mutational BurdenPaul A VanderLaan, Deepa Rangachari, Daniel B Costa
Cancer Cytopathology|August 7, 2020
The rapidly evolving landscape of biomarker testing in non-small cell lung cancerPaul A VanderLaan, Deepa Rangachari, Daniel B Costa
Pageof 18